Skip to main content

X4 Pharmaceuticals, Inc.

corporate_fare Company Profile

X4 Pharmaceuticals, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed XFOR - Latest Insights

XFOR
Mar 20, 2026, 8:49 AM EDT
Filing Type: DEFA14A
Importance Score:
7
X4 Pharmaceuticals Seeks Shareholder Approval to Increase Equity Incentive Plan Shares
Sentiment: Neutral
View Wiseek Article
XFOR
Mar 20, 2026, 8:45 AM EDT
Filing Type: DEF 14A
Importance Score:
7
X4 Pharmaceuticals Seeks Shareholder Approval for Expanded Equity Incentive Plan Amidst Going Concern Doubts
Sentiment: Neutral
View Wiseek Article
XFOR
Mar 17, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
9
EMA Recommends Mavorixafor Approval, X4 Pharma Secures Cash Runway Through 2028
Sentiment: Positive
View Wiseek Article
XFOR
Mar 17, 2026, 6:59 AM EDT
Filing Type: 10-K
Importance Score:
8
X4 Pharmaceuticals Reports Doubled Net Loss, Going Concern Doubt Amidst Major Equity Raises and Restructuring
Sentiment: Negative
View Wiseek Article
XFOR
Feb 27, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
Sentiment: Positive
View Wiseek Article